Last reviewed · How we verify
XaraColl
XaraColl is a bioabsorbable collagen matrix that delivers chlorhexidine locally to promote hemostasis and reduce infection in surgical wounds.
XaraColl is a bioabsorbable collagen matrix that delivers chlorhexidine locally to promote hemostasis and reduce infection in surgical wounds. Used for Hemostasis and infection prevention in surgical wounds, Use as an adjunct to hemostasis during general, cardiac, and vascular surgery.
At a glance
| Generic name | XaraColl |
|---|---|
| Also known as | Bupivacaine collagen implant |
| Sponsor | Innocoll |
| Drug class | Bioabsorbable hemostatic and antimicrobial wound matrix |
| Target | Chlorhexidine (broad-spectrum antimicrobial); collagen matrix (hemostatic scaffold) |
| Modality | Small molecule |
| Therapeutic area | Surgery/Wound Management |
| Phase | FDA-approved |
Mechanism of action
XaraColl combines a native collagen matrix with chlorhexidine gluconate, a broad-spectrum antimicrobial agent. The collagen provides a hemostatic scaffold that promotes clotting and wound healing, while the chlorhexidine is released locally to reduce bacterial colonization and infection risk. The matrix is gradually absorbed and replaced by native tissue.
Approved indications
- Hemostasis and infection prevention in surgical wounds
- Use as an adjunct to hemostasis during general, cardiac, and vascular surgery
Common side effects
- Surgical site infection
- Seroma formation
- Hematoma
- Wound dehiscence
Key clinical trials
- An Open-label Safety and Pharmacokinetic Study of INL-001 in Adults Following Various Open Soft-Tissue Surgeries (PHASE3)
- Efficacy and Safety Study of Postsurgical Analgesia With INL-001 in Abdominoplasty (PHASE3)
- Safety, Tolerability, PK, and Analgesic Effect of INL-001 in Children Following Open Inguinal Hernia Repair (PHASE3)
- Phase 3 Study of Efficacy and Safety of the XaraColl® Bupivacaine Implant After Hernioplasty (PHASE3)
- Phase 3 Study of Efficacy and Safety of the XaraColl® Bupivacaine Implant After Hernioplasty (PHASE3)
- Pharmacokinetics, Relative Bioavailability and Safety of Xaracoll Implant (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- XaraColl CI brief — competitive landscape report
- XaraColl updates RSS · CI watch RSS
- Innocoll portfolio CI